ClinicalTrials.gov
public full text
Public Domain
DORA and LP in Alzheimer's Disease Biomarkers
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid#886116
- Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer's Disease in the HABS-HD Study.#392950
- Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease#1072814
- Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease#853039
- Exploring the Recovery Function of Sleep in Neurodegeneration#865844
Record · ID 898630
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive